US Stem Cell Inc (USRM)

[4toSchool]

Why not receiving RMAT designation might be good for USRM Shareholders. IMO, the benefit to RMAT is largely being able to charge patients while reducing the number of patients needed for FDA approval. The "Right to Try" laws allow stem cell therapy providers to charge fees, so that negates RMAT's revenue benefit, leaving the number of patients needed to seek FDA approval. Do we as shareholders want less or more paying patients? I vote for more paying patients, means more revenue, meaning more profits, meaning higher pps.

I hope that insurers understand the benefit of reducing their costs too. They could save a lot of expense if they paid for stem cell therapy in "Right to Try" states versus paying for ongoing non-stem cell treatmnents.

Just my thoughts before the weekend kicks into gear.

GLTA

Go $USRM!!!!!!!